Plain-English translation of NCT06796114 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are studying blood samples from patients with advanced hepatocellular carcinoma (liver cancer) who are being treated with tremelimumab and durvalumab, a combination of two immunotherapy drugs. The goal is to find biological markers—measurable signs in your blood—that can predict which patients will respond well to this treatment and have better long-term survival.
Right now, doctors cannot reliably predict which patients with liver cancer will benefit from this immunotherapy combination. Some patients live much longer than others after receiving the same treatment, but we don't know why. By studying blood samples, researchers hope to discover early warning signs that show which patients are likely to respond well, so doctors can personalize treatment decisions in the future.
You likely qualify if…
You likely don't qualify if…
You will receive the tremelimumab and durvalumab treatment as part of your regular cancer care at the hospital. Researchers will collect blood samples from you at specific timepoints during and after your treatment to analyze for biomarkers. The study will follow your treatment response and track how long you survive. Beyond the blood draws, participation involves standard monitoring that you would likely receive anyway as part of your cancer treatment.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
France